<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Fertil Steril</journal-id><journal-id journal-id-type="iso-abbrev">Int J Fertil Steril</journal-id><journal-id journal-id-type="publisher-id">Royan Institute</journal-id><journal-title-group><journal-title>International Journal of Fertility &#x00026; Sterility</journal-title></journal-title-group><issn pub-type="ppub">2008-076X</issn><issn pub-type="epub">2008-0778</issn><publisher><publisher-name>Royan Institute</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25780518</article-id><article-id pub-id-type="pmc">4355923</article-id><article-id pub-id-type="other">Int-J-Fertil-Steril-8-373</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject><subj-group><subject>Gynecology and Female Infertility</subject><subject>Endocrinology and Metabolism</subject></subj-group></subj-group></article-categories><title-group><article-title>The Higher Response of Vascular Endothelial Growth
Factor and Angiotensin-II to Human Chorionic
Gonadotropin in Women with Polycystic
Ovary Syndrome</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Qu</surname><given-names>Junwei</given-names></name><degrees>Ph.D</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Che</surname><given-names>Yena</given-names></name><degrees>M.A.</degrees><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Pei</given-names></name><degrees>M.A</degrees><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Xia</surname><given-names>Yanjie</given-names></name><degrees>M.A</degrees><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Xiaoke</given-names></name><degrees>Ph.D</degrees><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Yong</given-names></name><degrees>Ph.D</degrees><xref ref-type="aff" rid="A2">2</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><aff id="A1"><label>1</label>Department of Gynecological Oncology Surgery, Jiangsu Cancer Hospital and Institute, Nanjing 210009,
China</aff><aff id="A2"><label>2</label>Translational Medicine Center and Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing
University, Nanjing 210093, China</aff><aff id="A3"><label>3</label>Department of Obstetrics and Gynecology, The First Affiliated Hospital, Heilongjiang University of Chinese
Medicine, Harbin 150040, China</aff></contrib-group><author-notes><corresp id="cor1"><label>* Corresponding Address:</label><addr-line>Translational Medicine Center and Jiangsu
Key Laboratory of Molecular Medicine</addr-line><institution>Medical School of Nanjing University</institution><addr-line>Nanjing</addr-line><addr-line>210093</addr-line><country>China</country>
Email:<email>yongwang@nju.edu.cn</email></corresp></author-notes><pub-date pub-type="ppub"><season>Jan-Mar</season><year>2015</year></pub-date><pub-date pub-type="epub"><day>7</day><month>2</month><year>2015</year></pub-date><volume>8</volume><issue>4</issue><fpage>373</fpage><lpage>378</lpage><history><date date-type="received"><day>1</day><month>10</month><year>2011</year></date><date date-type="accepted"><day>27</day><month>10</month><year>2013</year></date></history><permissions><copyright-statement>Any use, distribution, reproduction or abstract of this publication in any medium, with the exception of commercial purposes, is permitted provided the original work is properly cited</copyright-statement><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>This is an open-access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
</license-p></license></permissions><abstract><sec><title>Background</title><p>This research investigated the response of vascular active factors, vascular
endothelial growth factor (VEGF) and angiotensin-II (AT-II) to ovarian stimulation during 24 hours in patients with polycystic ovary syndrome (PCOS).</p></sec><sec><title>Materials and Methods</title><p>In this clinical trial study, 52 patients with PCOS and 8 control
cases were stimulated with human chorionic gonadotropin (HCG) on the 4<sup>th</sup> to 7<sup>th</sup> day
of the patients&#x02019; natural or induced menstrual cycles. We measured VEGF and AT-II by
radioimmunoassay before the injection (0 hour) and 3, 8, 12, 18 and 24 hours after the
stimulation.</p></sec><sec><title>Results</title><p>After ovarian stimulation, there was substantially higher level of VEGF in
typical PCOS patients than the other three groups at the 3 hour time point (p&#x0003c;0.05),
while there were no significant differences in VEGF at all the other time points
among the four groups. As for AT-II, before and at all time points after the ovarian
stimulation, it seemed that the AT-II levels in patients&#x02019; sera with different phenotypes of PCOS by the Rotterdam criteria were all higher than in the control group
although the differences were not statistically significant. The level of AT-II in typical PCOS patients was also significantly higher than the other three groups at the 3
hour time point (p&#x0003c;0.05), while no significant differences at all the other time points
among the four groups were observed.</p></sec><sec><title>Conclusion</title><p>The response to the stimulation varied among patients with different phenotypes of PCOS according to the Rotterdam criteria. Serum VEGF and AT-II were possible contributors to an increased risk of developing ovarian hyperstimulation syndrome
(OHSS) in patients with typical PCOS during the early follicular phase (3 hours) after
ovarian stimulation (Registration Number: NCT02265861).</p></sec></abstract><kwd-group><kwd>Polycystic Ovary Syndrome</kwd><kwd>Vascular Endothelial Growth Factor</kwd><kwd>Angiotensin-II</kwd><kwd>Ovarian Hyperstimulation Syndrome</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>Citation</meta-name><meta-value>Qu J, Che Y, Xu P, Xia Y, Wu X, Wang Y. The higher response of vascular endothelial growth factor and
angiotensin-II to human chorionic gonadotropin in women with polycystic ovary syndrome. Int J Fertil Steril. 2015; 8(4):
373-378.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Polycystic ovary syndrome (PCOS) is a complex and common gynecological endocrine disorder that occurs in 5-10% of reproductive women (<xref rid="B1" ref-type="bibr">1</xref>). In China, this disorder is found in 50-60% of outpatients in gynecologic endocrinopathy clinics (<xref rid="B2" ref-type="bibr">2</xref>). It is characterized by a polycystic ovary, ovarian hyperandrogenism (HA), and anovulation although there are several different phenotypes of PCOS according to the Rotterdam criteria (<xref rid="B3" ref-type="bibr">3</xref>). A key pathophysiological feature of PCOS is an increase in ovarian mass caused by new blood vessel proliferation in the stroma and theca interna (<xref rid="B4" ref-type="bibr">4</xref>). Ultrasonographic assessment of the stromal area and blood flow is currently used as a diagnostic test (<xref rid="B5" ref-type="bibr">5</xref>). In ovarian hyperstimulation syndrome (OHSS), massive ovarian enlargement has been reported with PCOS as one of its risk factors (<xref rid="B6" ref-type="bibr">6</xref>). Vascular active factors, such as vascular endothelial growth factor (VEGF), angiotensin-II (AT-II), insulin-like growth factor-1 (IGF-1), and some cytokines may be involved which have certain relevance for PCOS pathophysiology (<xref rid="B7" ref-type="bibr">7</xref>). Ovarian stimulation may change the production of vascular active factors and different phenotypes of PCOS may have different responses to the stimulation.</p><p>VEGF is a 46 kd dimeric protein. Its expression is increased where vascular proliferation is active. The most important sources of VEGF in the female reproductive system are local macrophages and granulosa cells, and the production of VEGF can be increased by human chorionic gonadotropin (HCG) (<xref rid="B8" ref-type="bibr">8</xref>). VEGF is one of the most likely candidates for promoting angiogenesis in PCOS and OHSS. The serum VEGF level is increased both in the patients with PCOS and OHSS (<xref rid="B9" ref-type="bibr">9</xref>). The increased number of actively secreting granulosa lutein cells and the increased secretory capacity of each granulosa cell both contribute to excessive VEGF production (<xref rid="B10" ref-type="bibr">10</xref>).</p><p>In PCOS, the Renin-Angiotensin System (RAS) is accentuated. The roles of AT-II have been proposed in growth and atresia of follicles, oocyte maturation, ovulation, corpus luteum formation, steroidogenesis, and corpus luteum regression (<xref rid="B11" ref-type="bibr">11</xref>). The level of AT-II in peripheral blood is higher in PCOS patients than in non-PCOS women. AT-II concentration is positively correlated with the level of testosterone (T) in PCOS patients (<xref rid="B12" ref-type="bibr">12</xref>). Therefore, components of the RAS, such as AT-II, may be involved in PCOS pathophysiology.</p><p>VEGF and AT-II belong to different molecular systems, however both can act as vascular active factors. The aim of this study is to investigate whether ovarian stimulation increases serum vascular active factors such as VEGF and AT-II within 24 hours after stimulation in patients with PCOS during the early follicular phase.</p></sec><sec sec-type="materials|methods"><title>Materials and Methods</title><p>This clinical trial study enrolled women with or without PCOS who entered an <italic>in vitro</italic> fertilization (IVF) program at the hospital affiliated to the Medical School of Nanjing University. This research was approved by the Medical Ethics Committee of the school and informed consent was obtained from the participating subjects. A total of 60 women were recruited and divided into four groups by the Rotterdam criteria according to three typical characteristics: 1. biochemical characteristics of HA, 2. chronic anovulation, and 3. polycystic ovarian morphology (PCO). Group 1 (typical PCOS) was composed of 21 women who had all three of the above features, group 2 (PCOS without PCO) included 14 women with both biochemical characteristics of HA and chronic anovulation, group 3 (PCOS without HA) included 17 women with both chronic anovulation and PCO, and group 4 consisted of 8 volunteers without any biochemical characteristics of HA, chronic anovulation or PCO. This group served as the controls for the three PCOS groups. No patients were prescribed any hormonal prescriptions during the three months preceding the study. The clinical manifestations and the basic data are shown in <xref ref-type="table" rid="T1">table 1</xref>.</p><p>An ovarian stimulation test, which mimicked the common ovulation protocol (<xref rid="B10" ref-type="bibr">10</xref>) was performed by the administration of a single intramuscular (i.m.) injection of HCG (5000 IU, The First Biochemical Pharmapeutic, Shanghai, China) during the early follicular phase of the same menstrual cycle (4<sup>th</sup> to 7<sup>th</sup> day of the cycle).</p><p>Blood samples from all subjects were collected immediately prior to the injection (H0), and at 3 (H1), 8 (H2), 12 (H3), 18 (H4), and 24 (H5) hours after the injection. The serum was stored at -80&#x002da;C until further analyses of VEGF and AT-II levels by immunoradioassay. Concentrations of androstenedione (A), T and estradiol (E<sub>2</sub>) at H0 were also measured.</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p> Basic clinical and hormonal profiles in the four groups</p></caption><table frame="hsides" rules="groups"><tbody><tr><th colspan="5" rowspan="1"><hr/></th></tr><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Group 1</th><th align="left" rowspan="1" colspan="1">Group 2</th><th align="left" rowspan="1" colspan="1">Group 3</th><th align="left" rowspan="1" colspan="1">Group 4</th></tr><tr><th colspan="5" rowspan="1"><hr/></th></tr><tr><td align="left" rowspan="1" colspan="1"><bold>N</bold></td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">8</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Age (Y)</bold></td><td rowspan="1" colspan="1">30.1&#x000b1; 4.03</td><td rowspan="1" colspan="1">30.5&#x000b1; 3.69</td><td rowspan="1" colspan="1">31.0 &#x000b1; 4.12</td><td rowspan="1" colspan="1">29.5 &#x000b1; 5.12</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>BMI (kg/m<sup>2</sup>)</bold></td><td rowspan="1" colspan="1">24.5&#x000b1; 1.29</td><td rowspan="1" colspan="1">23.5&#x000b1; 0.8</td><td rowspan="1" colspan="1">22.3 &#x000b1; 0.99</td><td rowspan="1" colspan="1">22.4 &#x000b1; 0.76</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>WHR</bold></td><td rowspan="1" colspan="1">0.82&#x000b1; 0.02</td><td rowspan="1" colspan="1">0.80&#x000b1; 0.02</td><td rowspan="1" colspan="1">0.80 &#x000b1; 0.02</td><td rowspan="1" colspan="1">0.78 &#x000b1; 0.02</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>T (nmol/L)</bold></td><td rowspan="1" colspan="1">2.09&#x000b1; 0.14 <sup>a, b</sup></td><td rowspan="1" colspan="1">2.09&#x000b1; 0.12 <sup>a , b</sup></td><td rowspan="1" colspan="1">1.22 &#x000b1; 0.13</td><td rowspan="1" colspan="1">0.73 &#x000b1; 0.14</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>FTI</bold></td><td rowspan="1" colspan="1">10.76 &#x000b1; 1.57 <sup>a, b</sup></td><td rowspan="1" colspan="1">6.44&#x000b1; 0.7</td><td rowspan="1" colspan="1">3.52 &#x000b1; 0.62</td><td rowspan="1" colspan="1">1.58 &#x000b1; 0.48</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>A (nmol/L)</bold></td><td rowspan="1" colspan="1">9.56&#x000b1; 0.63 <sup>a, b</sup></td><td rowspan="1" colspan="1">8.07&#x000b1; 0.8 <sup>a</sup></td><td rowspan="1" colspan="1">6.97 &#x000b1; 0.62</td><td rowspan="1" colspan="1">4.47 &#x000b1; 0.36</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>E<sub>2</sub> (pg/ml)</bold></td><td rowspan="1" colspan="1">34.9&#x000b1; 5.09</td><td rowspan="1" colspan="1">37.5&#x000b1; 5.48</td><td rowspan="1" colspan="1">29.2 &#x000b1; 2.57</td><td rowspan="1" colspan="1">30.8 &#x000b1; 3.26</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>E<sub>2</sub>/T</bold></td><td rowspan="1" colspan="1">17.8&#x000b1; 2.73<sup>a</sup></td><td rowspan="1" colspan="1">18.8&#x000b1; 5.76<sup>a</sup></td><td rowspan="1" colspan="1">33.9 &#x000b1; 8.15</td><td rowspan="1" colspan="1">78.0 &#x000b1; 37.8</td></tr><tr><th colspan="5" rowspan="1"><hr/></th></tr></tbody></table><table-wrap-foot><fn><p>Note: A total of 60 women were recruited and divided into four groups by the Rotterdam criteria. a; P&#x0003c;0.05 vs. group 4, b; P&#x0003c;0.05 vs. group 3, BMI; Body mass index, WHR; Waist to hip ratio, T; Testosterone, FTI; Free testosterone index, A; Androstenedione and E<sub>2</sub>: Estradiol.</p><p>Among the groups there were no differences in age, BMI and WHR. The T, A, and E<sub>2</sub> levels of the polycystic ovary syndrome (PCOS) groups were significantly higher than the control group.</p></fn></table-wrap-foot></table-wrap><sec><title>Statistical analysis</title><p>Tests were two-sided and conducted at &#x003b1; &#x0003c;0.05. In general, the methods for the multiple comparisons were based on analysis of variance (ANOVA) and analysis of covariance (ANCOVA) to identify group differences with the Bonferroni correction when appropriate. Logarithmic transformation of data was performed for data that were not normally distributed. For all analyses, a two-tailed p&#x0003c;0.05 was considered statistically significant. Unless otherwise noted, all results were described as mean &#x000b1; SD. Correlations were examined by linear regression analysis. Statistical analysis was performed using the SPSS 11.0 software package for Windows.</p></sec></sec><sec sec-type="results"><title>Results</title><p>The subject characteristics of the four groups are summarized in <xref ref-type="table" rid="T1">table 1</xref>. Among the groups there were no differences in age, body mass index (BMI) and waist to hip ratio (WHR). There were significantly higher T, A, and E<sub>2</sub> levels of the PCOS groups compared to the control group (<xref ref-type="table" rid="T1">Table 1</xref>).</p><p>Before ovarian stimulation, there were no significant differences in VEGF between the four groups (<xref ref-type="fig" rid="F1">Fig 1A</xref>). After ovarian stimulation, the level of VEGF in the typical PCOS patients (Group 1) was substantially higher than the other three groups at the 3 hour time point (p&#x0003c;0.05), while there were no significant differences in VEGF at the other time points among the four groups (<xref ref-type="fig" rid="F1">Fig 1A</xref>). As for AT-II, before and at all time points after ovarian stimulation, it appeared that AT-II levels in the patients&#x02019; sera with different phenotypes of PCOS according to the Rotterdam criteria were all higher than in the control group (<xref ref-type="fig" rid="F1">Fig 1B</xref>), however these differences were not statistically significant. The level of AT-II in typical PCOS patients (Group 1) was also significantly higher than the other three groups at the 3 hour time point (p&#x0003c;0.05), while no significant differences at all the other time points among the four groups (<xref ref-type="fig" rid="F1">Fig 1B</xref>) were observed.</p><fig id="F1" orientation="portrait" position="float"><label>Fig 1</label><caption><p>Vascular endothelial growth factor (VEGF) (A) and angiotensin II (AT- II) (B) response to stimuli during the ovarian stimulation test.</p><p>The level of VEGF and AT- II in typical polycystic ovary syndrome (PCOS) patients (group 1) was substantially higher than the other three groups at the 3 hour time point.</p><p>Note: Logarithmic transformation of data was performed for measures that were not normally distributed. All results are expressed as Log<sup>10</sup> (<overline>x</overline> &#x000b1; s). *; P&#x0003c;0.05, PCO; Polycystic ovarian morphology and HA; Hyperandrogenism.</p></caption><graphic xlink:href="Int-J-Fertil-Steril-8-373-g01"/></fig></sec><sec sec-type="discussion"><title>Discussion</title><p>Abnormal expression of VEGF, accompanied by abnormal angiogenesis and vascular permeability has been suggested as a cause of several diseases including PCOS and OHSS (<xref rid="B13" ref-type="bibr">13</xref>-<xref rid="B16" ref-type="bibr">16</xref>). Increased secretion of VEGF in the serum of patients with PCOS may be induced as a result of an increased number of actively secreting granulosa lutein cells that have both increased secretory capacity and upregulated gene expression level (<xref rid="B17" ref-type="bibr">17</xref>). The expression level of VEGF is increased in the hyper-echogenic stroma of PCOS and it induces subsequent stroma growth by promoting microvascular permeability (<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>). Androgen is secreted in the theca interna and the latter will grow abnormally where vascular proliferation is active. VEGF can affect vascular endothelial cell proliferation and vascular permeability (<xref rid="B20" ref-type="bibr">20</xref>). PCOS is one of the risk factors of OHSS (<xref rid="B21" ref-type="bibr">21</xref>). The significance of VEGF is its contribution to the induction and progression of OHSS during ovarian induction. VEGF has also been suggested to be responsible for OHSS which is an iatrogenic and potentially life-threatening complication of ovulation induction for the treatment of infertility. Our findings have demonstrated that ovarian stimulation increased VEGF expression during the early follicular phase of typical PCOS patients, which indicated that VEGF might be directly involved in OHSS pathogenesis (<xref rid="B22" ref-type="bibr">22</xref>).</p><p>Despite the fact that OHSS occurs in the luteal phase after ovarian induction, we have proposed that VEGF should be monitored during the early follicular phase. However, in this study, the level of VEGF in the PCOS without PCO or HA did not significantly increase. This phenomenon has demonstrated that the responsiveness of patients with typical PCOS to ovarian stimulation was greater than that of the PCOS without PCO or HA. As we know, women of both typical PCOS and PCOS without HA are at higher risks for OHSS (<xref rid="B23" ref-type="bibr">23</xref>). However according to our observation, the VEGF response patterns in these two groups differed; group 1 was more sensitive than group 3. This phenomenon may suggest that the typical PCOS is more severe than the phenotypic PCOS. Further research is needed to clarify this phenomenon.</p><p>AT-II plays an important role in RAS and it affects the reproduction cycle at different stages (<xref rid="B24" ref-type="bibr">24</xref>). Disturbances in ovarian RAS can be the cause or the result of such reproductive disorders as PCOS and OHSS. Our data have demonstrated that ovarian stimulation led to AT-II expression in patients with typical PCOS. Consistent with a previous report, AT-II might play an important role in PCOS pathophysiology (<xref rid="B25" ref-type="bibr">25</xref>). AT-II has been shown to modulate the local functions of ovaries, such as ovarian steroidogenesis and formation of the corpus luteum, in addition to stimulation of oocyte maturation and ovulation via AT-II receptors on granulosa cells (<xref rid="B26" ref-type="bibr">26</xref>).</p><p>In addition to the circulating RAS, the ovary has been recently demonstrated to exhibit its own RAS products and activities. Such an intrinsic RAS can modulate the local functions of ovaries such as follicular development, ovulation, and formation of the corpus luteum (<xref rid="B27" ref-type="bibr">27</xref>). As AT-II is mainly produced by follicular theca cells and granulosa lutein cells (<xref rid="B28" ref-type="bibr">28</xref>), patients with PCOS have a higher risk of developing OHSS because of exogenous gonadotropin for ovulation induction. Results of these studies indicate that RAS is more active in the ovaries of PCOS patients.</p><p>Although OHSS occurs during the luteal phases, the current study was performed during the follicular phase. Ovarian stimulation increased the AT-II levels during the follicular phase in PCOS patients. These results, taken together with other parallel studies (<xref rid="B29" ref-type="bibr">29</xref>), led us to consider serum AT-II as a possible contributor to a greater risk of OHSS in patients with PCOS during ovulation induction. Inhibition of RAS, commensurate with the changes of serum AT-II concentrations, might be used as a therapeutic approach.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>In conclusion, the response of the ovaries to HCG stimulation differs in patients with different phenotypes of PCOS according to the Rotterdam criteria. The typical PCOS is more severe than the phenotypic PCOS. Further research is needed to clarify this phenomenon. Serum VEGF and AT-II levels may be considered as biomarkers to predict risks of developing OHSS in patients with typical PCOS during the early follicular phase, at 3 hours after ovarian stimulation.</p></sec></body><back><ack><p>The authors thank the Nature Science Foundation of China (30672228) and the National Basic Research Program of China (The 973 Programme 2010CB945103) for their financial support. The authors have no conflict of interest.</p></ack><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Yi</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name></person-group><article-title>A microsatellite polymorphism (tttta)n in the promoter of the CYP11a gene in Chinese women with polycystic ovary syndrome</article-title><source>Fertil Steril</source><year>2006</year><volume>86</volume><issue>1</issue><fpage>223</fpage><lpage>226</lpage><pub-id pub-id-type="pmid">16764871</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Yi</surname><given-names>L</given-names></name><name><surname>Fan</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name></person-group><article-title>Polymorphisms of the peroxisome proliferator-activated receptor-gamma and its coactivator-1alpha genes in Chinese women with polycystic ovary syndrome</article-title><source>Fertil Steril</source><year>2006</year><volume>85</volume><issue>5</issue><fpage>1536</fpage><lpage>1540</lpage><pub-id pub-id-type="pmid">16600233</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>P</given-names></name><name><surname>Shen</surname><given-names>SM</given-names></name><name><surname>Zhang</surname><given-names>XL</given-names></name><name><surname>Liang</surname><given-names>F</given-names></name><name><surname>Xie</surname><given-names>GB</given-names></name><name><surname>Yi</surname><given-names>L</given-names></name><etal/></person-group><article-title>Haplotype analysis of single nucleotide polymorphisms in anti-M&#x000fc;llerian hormone gene in Chinese PCOS women</article-title><source>Arch Gynecol Obstet</source><year>2013</year><volume>288</volume><issue>1</issue><fpage>125</fpage><lpage>130</lpage><pub-id pub-id-type="pmid">23371438</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Speca</surname><given-names>S</given-names></name><name><surname>Napolitano</surname><given-names>C</given-names></name><name><surname>Tagliaferri</surname><given-names>G</given-names></name></person-group><article-title>The pathogenetic enigma of polycystic ovary syndrome</article-title><source>J Ultrasound</source><year>2007</year><volume>10</volume><issue>4</issue><fpage>153</fpage><lpage>160</lpage><pub-id pub-id-type="pmid">23396998</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zackova</surname><given-names>T</given-names></name><name><surname>Jarvela</surname><given-names>IY</given-names></name><name><surname>Tapanainen</surname><given-names>JS</given-names></name><name><surname>Feyereisl</surname><given-names>J</given-names></name></person-group><article-title>Assessment of endometrial and ovarian characteristics using three dimensional power Doppler ultrasound to predict response in frozen embryo transfer cycles</article-title><source>Reprod Biol Endocrinol</source><year>2009</year><volume>7</volume><fpage>151</fpage><lpage>158</lpage><pub-id pub-id-type="pmid">20035622</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dahl</surname><given-names>SK</given-names></name><name><surname>Cannon</surname><given-names>S</given-names></name><name><surname>Aubuchon</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>DB</given-names></name><name><surname>Robins</surname><given-names>JC</given-names></name><name><surname>Thomas</surname><given-names>MA</given-names></name></person-group><article-title>Follicle curetting at the time of oocyte retrieval increases the oocyte yield</article-title><source>J Assist Reprod Genet</source><year>2009</year><volume>26</volume><issue>6</issue><fpage>335</fpage><lpage>339</lpage><pub-id pub-id-type="pmid">19548079</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escobar-Morreale</surname><given-names>HF</given-names></name><name><surname>Luque-Ramirez</surname><given-names>M</given-names></name><name><surname>Gonzalez</surname><given-names>F</given-names></name></person-group><article-title>Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis</article-title><source>Fertil Steril</source><year>2011</year><volume>95</volume><issue>3</issue><fpage>1048</fpage><lpage>1058</lpage><pub-id pub-id-type="pmid">21168133</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harada</surname><given-names>M</given-names></name><name><surname>Peegel</surname><given-names>H</given-names></name><name><surname>Menon</surname><given-names>KM</given-names></name></person-group><article-title>Expression of vascular endothelial growth factor A during ligand-induced down-regulation of luteinizing hormone receptor in the ovary</article-title><source>Mol Cell Endocrinol</source><year>2010</year><volume>328</volume><issue>1-2</issue><fpage>28</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">20619315</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Julio-Pieper</surname><given-names>M</given-names></name><name><surname>Lozada</surname><given-names>P</given-names></name><name><surname>Tapia</surname><given-names>V</given-names></name><name><surname>Vega</surname><given-names>M</given-names></name><name><surname>Miranda</surname><given-names>C</given-names></name><name><surname>Vantman</surname><given-names>D</given-names></name><etal/></person-group><article-title>Nerve growth factor induces vascular endothelial growth factor expression in granulosa cells via a trkA receptor/mitogen-activated protein kinase-extracellularly regulated kinase 2-dependent pathway</article-title><source>J Clin Endocrinol Metab</source><year>2009</year><volume>94</volume><issue>8</issue><fpage>3065</fpage><lpage>3071</lpage><pub-id pub-id-type="pmid">19454577</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tokuyama</surname><given-names>O</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Muso</surname><given-names>A</given-names></name><name><surname>Fujino</surname><given-names>Y</given-names></name><name><surname>Ishiko</surname><given-names>O</given-names></name><name><surname>Ogita</surname><given-names>S</given-names></name></person-group><article-title>Vascular endothelial growth factor concentrations in follicular fluid obtained from IVF-ET patients: a comparison of hMG, clomiphene citrate, and natural cycle</article-title><source>J Assist Reprod Genet</source><year>2002</year><volume>19</volume><issue>1</issue><fpage>19</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">11893011</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gard</surname><given-names>PR</given-names></name></person-group><article-title>Implications of the angiotensin converting enzyme gene insertion/deletion polymorphism in health and disease: a snapshot review</article-title><source>Int J Mol Epidemiol Genet</source><year>2010</year><volume>1</volume><issue>2</issue><fpage>145</fpage><lpage>157</lpage><pub-id pub-id-type="pmid">21537387</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alphan</surname><given-names>Z</given-names></name><name><surname>Berberoglu</surname><given-names>Z</given-names></name><name><surname>Gorar</surname><given-names>S</given-names></name><name><surname>Candan</surname><given-names>Z</given-names></name><name><surname>Aktas</surname><given-names>A</given-names></name><name><surname>Aral</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Increased total Renin levels but not Angiotensin-converting enzyme activity in obese patients with polycystic ovary syndrome</article-title><source>Med Princ Pract</source><year>2013</year><volume>22</volume><issue>5</issue><fpage>475</fpage><lpage>479</lpage><pub-id pub-id-type="pmid">23899907</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sohrabvand</surname><given-names>F</given-names></name><name><surname>Ansaripour</surname><given-names>S</given-names></name><name><surname>Bagheri</surname><given-names>M</given-names></name><name><surname>Shariat</surname><given-names>M</given-names></name><name><surname>Jafarabadi</surname><given-names>M</given-names></name></person-group><article-title>Cabergoline versus coasting in the prevention of ovarian hyperstimulation syndrome and assisted reproductive technologies outcome in high risk patients</article-title><source>Int J Fertil Steril</source><year>2009</year><volume>3</volume><issue>1</issue><fpage>35</fpage><lpage>40</lpage></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez</surname><given-names>R</given-names></name><name><surname>Ferrero</surname><given-names>H</given-names></name><name><surname>Delgado-Rosas</surname><given-names>F</given-names></name><name><surname>Gaytan</surname><given-names>M</given-names></name><name><surname>Morales</surname><given-names>C</given-names></name><name><surname>Zimmermann</surname><given-names>RC</given-names></name><etal/></person-group><article-title>Evidences for the existence of a low dopaminergic tone in polycystic ovarian syndrome: implications for OHSS development and treatment</article-title><source>J Clin Endocrinol Metab</source><year>2011</year><volume>96</volume><issue>8</issue><fpage>2484</fpage><lpage>2492</lpage><pub-id pub-id-type="pmid">21646367</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>MJ</given-names></name><name><surname>Chason</surname><given-names>RJ</given-names></name><name><surname>Payson</surname><given-names>MD</given-names></name><name><surname>Segars</surname><given-names>JH</given-names></name><name><surname>Csokmay</surname><given-names>JM</given-names></name></person-group><article-title>GnRH antagonist rescue in high responders at risk for OHSS results in excellent assisted reproduction outcomes</article-title><source>Reprod Biomed Online</source><year>2012</year><volume>25</volume><issue>3</issue><fpage>284</fpage><lpage>291</lpage><pub-id pub-id-type="pmid">22796230</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vural</surname><given-names>P</given-names></name><name><surname>Kusku-Kiraz</surname><given-names>Z</given-names></name><name><surname>Dogru-Abbasoglu</surname><given-names>S</given-names></name><name><surname>Cil</surname><given-names>E</given-names></name><name><surname>Karadag</surname><given-names>B</given-names></name><name><surname>Akgul</surname><given-names>C</given-names></name><etal/></person-group><article-title>Vascular endothelial growth factor -2578 A/C, -460 T/C and +405 G/C polymorphisms in polycystic ovary syndrome</article-title><source>Eur J Obstet Gynecol Reprod Biol</source><year>2009</year><volume>147</volume><issue>1</issue><fpage>57</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">19631445</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiao</surname><given-names>J</given-names></name><name><surname>Feng</surname><given-names>HL</given-names></name></person-group><article-title>Extra- and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence</article-title><source>Hum Reprod Update</source><year>2011</year><volume>17</volume><issue>1</issue><fpage>17</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">20639519</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bates</surname><given-names>DO</given-names></name></person-group><article-title>Vascular endothelial growth factors and vascular permeability</article-title><source>Cardiovasc Res</source><year>2010</year><volume>87</volume><issue>2</issue><fpage>262</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">20400620</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Behery</surname><given-names>MM</given-names></name><name><surname>Diab</surname><given-names>AE</given-names></name><name><surname>Mowafy</surname><given-names>H</given-names></name><name><surname>Ebrahiem</surname><given-names>MA</given-names></name><name><surname>Shehata</surname><given-names>AE</given-names></name></person-group><article-title>Effect of laparoscopic ovarian drilling on vascular endothelial growth factor and ovarian stromal blood flow using 3-dimensional power Doppler</article-title><source>Int J Gynaecol Obstet</source><year>2011</year><volume>112</volume><issue>2</issue><fpage>119</fpage><lpage>121</lpage><pub-id pub-id-type="pmid">21144516</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brogan</surname><given-names>RS</given-names></name><name><surname>Mix</surname><given-names>S</given-names></name><name><surname>Puttabyatappa</surname><given-names>M</given-names></name><name><surname>VandeVoort</surname><given-names>CA</given-names></name><name><surname>Chaffin</surname><given-names>CL</given-names></name></person-group><article-title>Expression of the insulin-like growth factor and insulin systems in the luteinizing macaque ovarian follicle</article-title><source>Fertil Steril</source><year>2010</year><volume>93</volume><issue>5</issue><fpage>1421</fpage><lpage>1429</lpage><pub-id pub-id-type="pmid">19243760</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pundir</surname><given-names>J</given-names></name><name><surname>Sunkara</surname><given-names>SK</given-names></name><name><surname>El-Toukhy</surname><given-names>T</given-names></name><name><surname>Khalaf</surname><given-names>Y</given-names></name></person-group><article-title>Meta-analysis of GnRH antagonist protocols: do they reduce the risk of OHSS in PCOS?</article-title><source>Reprod Biomed Online</source><year>2012</year><volume>24</volume><issue>1</issue><fpage>6</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">22133908</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beigi Boroujeni</surname><given-names>M</given-names></name><name><surname>Beigi Boroujeni</surname><given-names>N</given-names></name><name><surname>Salehnia</surname><given-names>M</given-names></name><name><surname>Marandi</surname><given-names>E</given-names></name></person-group><article-title>Ultrastructural changes of corpus luteum after ovarian stimulation at implantation period</article-title><source>Iran Biomed J</source><year>2012</year><volume>16</volume><issue>1</issue><fpage>33</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">22562030</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Battaglia</surname><given-names>C</given-names></name><name><surname>Mancini</surname><given-names>F</given-names></name><name><surname>Persico</surname><given-names>N</given-names></name><name><surname>Zaccaria</surname><given-names>V</given-names></name><name><surname>de Aloysio</surname><given-names>D</given-names></name></person-group><article-title>Ultrasound evaluation of PCO, PCOS and OHSS</article-title><source>Reprod Biomed Online</source><year>2004</year><volume>9</volume><issue>6</issue><fpage>614</fpage><lpage>619</lpage><pub-id pub-id-type="pmid">15670405</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayden</surname><given-names>MR</given-names></name><name><surname>Sowers</surname><given-names>KM</given-names></name><name><surname>Pulakat</surname><given-names>L</given-names></name><name><surname>Joginpally</surname><given-names>T</given-names></name><name><surname>Krueger</surname><given-names>B</given-names></name><name><surname>Whaley-Connell</surname><given-names>A</given-names></name><etal/></person-group><article-title>Possible Mechanisms of Local Tissue Renin-Angiotensin System Activation in the Cardiorenal Metabolic Syndrome and Type 2 Diabetes Mellitus</article-title><source>Cardiorenal Med</source><year>2011</year><volume>1</volume><issue>3</issue><fpage>193</fpage><lpage>210</lpage><pub-id pub-id-type="pmid">22096455</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arefi</surname><given-names>S</given-names></name><name><surname>Mottaghi</surname><given-names>S</given-names></name><name><surname>Sharifi</surname><given-names>AM</given-names></name></person-group><article-title>Studying the correlation of renin-angiotensin-system (RAS) components and insulin resistance in polycystic ovary syndrome (PCOs)</article-title><source>Gynecol Endocrinol</source><year>2013</year><volume>29</volume><issue>5</issue><fpage>470</fpage><lpage>473</lpage><pub-id pub-id-type="pmid">23461768</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milsted</surname><given-names>A</given-names></name><name><surname>Underwood</surname><given-names>AC</given-names></name><name><surname>Dunmire</surname><given-names>J</given-names></name><name><surname>DelPuerto</surname><given-names>HL</given-names></name><name><surname>Martins</surname><given-names>AS</given-names></name><name><surname>Ely</surname><given-names>DL</given-names></name><etal/></person-group><article-title>Regulation of multiple renin-angiotensin system genes by Sry</article-title><source>J Hypertens</source><year>2010</year><volume>28</volume><issue>1</issue><fpage>59</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">19809364</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cherry</surname><given-names>JA</given-names></name><name><surname>Hou</surname><given-names>X</given-names></name><name><surname>Rueda</surname><given-names>BR</given-names></name><name><surname>Davis</surname><given-names>JS</given-names></name><name><surname>Townson</surname><given-names>DH</given-names></name></person-group><article-title>Microvascular endothelial cells of the bovine corpus luteum: a comparative examination of the estrous cycle and pregnancy</article-title><source>J Reprod Dev</source><year>2008</year><volume>54</volume><issue>3</issue><fpage>183</fpage><lpage>191</lpage><pub-id pub-id-type="pmid">18296866</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alper</surname><given-names>MM</given-names></name><name><surname>Smith</surname><given-names>LP</given-names></name><name><surname>Sills</surname><given-names>ES</given-names></name></person-group><article-title>Ovarian hyperstimulation syndrome: current views on pathophysiology, risk factors, prevention, and management</article-title><source>J Exp Clin Assist Reprod</source><year>2009</year><volume>6</volume><fpage>3</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">20485578</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>JS</given-names></name><name><surname>Rueda</surname><given-names>BR</given-names></name><name><surname>Spanel-Borowski</surname><given-names>K</given-names></name></person-group><article-title>Microvascular endothelial cells of the corpus luteum</article-title><source>Reprod Biol Endocrinol</source><year>2003</year><volume>1</volume><fpage>89</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">14613535</pub-id></element-citation></ref></ref-list></back></article>